Phenotypes of Allo- and Autoimmune Antibody Responses to FVIII Characterized by Surface Plasmon Resonance

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Lewis, Kenneth B ^a   Hughes, Richard J ^b   Epstein, Melinda S ^b   Josephson, Neil C ^a,c   Kempton, Christine L ^d   Kessler, Craig M ^e   Key, Nigel S ^f   Howard, Tom E ^b,g   Kruse Jarres, Rebecca ^h   Lusher, Jeanne M ⁱ   Walsh, Christopher E ^j   Watts, Raymond G ^k   Ettinger, Ruth A ^a   Pratt, Kathleen P ^a,c,l  

^a PUGET SOUND BLOOD CENTER   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d EMORY UNIVERSITY   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f UNIVERSITY OF NORTH CAROLINA   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h TULANE UNIVERSITY   (United States)

ⁱ WAYNE STATE UNIVERSITY   (United States)

^j MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^l UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; AUTOANTIBODY; BLOOD CLOTTING FACTOR 8; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G4; MONOCLONAL ANTIBODY; VON WILLEBRAND FACTOR;

ADOLESCENT; ADULT; AGED; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; DISEASE SEVERITY; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; PRESCHOOL CHILD; PROTEIN PROTEIN INTERACTION; SCHOOL CHILD; SURFACE PLASMON RESONANCE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNOGLOBULIN G; MICE; PHENOTYPE; SURFACE PLASMON RESONANCE;

EID: 84877308750     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061120     Document Type: Article

References (44)

1. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, et al. (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339: 594-598.
2. Kasper CK, Aledort L, Aronson D, Counts R, Edson JR, et al. (1975) Proceedings: A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 34: 612.
3. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, et al. (1995) The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 73: 247-251.
4. Sahud MA, Pratt KP, Zhukov O, Qu K, Thompson AR, (2007) ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 13: 317-322.
5. Zakarija A, Harris S, Rademaker AW, Brewer J, Krudysz-Amblo J, et al. (2011) Alloantibodies to factor VIII in haemophilia. Haemophilia 17: 636-640.
6. Krudysz-Amblo J, Parhami-Seren B, Butenas S, Brummel-Ziedens KE, Gomperts ED, et al. (2009) Quantitation of anti-factor VIII antibodies in human plasma. Blood 113: 2587-2594.
7. Towfighi F, Gharagozlou S, Sharifian RA, Kazemnejad A, Esmailzadeh K, et al. (2005) Comparative measurement of anti factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol 114: 84-90.
8. Shetty S, Ghosh K, Mohanty D, (2003) An ELISA assay for the detection of factor VIII antibodies- comparison with the conventional Bethesda assay in a large cohort of haemophilia samples. Acta Haematol 109: 18-22.
9. Irigoyen MB, Primiani L, Felippo M, Candela M, Bianco RP, et al. (2011) A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay. Haemophilia 17: 267-274.
10. Pratt KP, Thompson AR, (2009) B-Cell and T-Cell epitopes in anti-factor VIII immune responses. Clin Rev Allergy Immunol 37: 80-95.
11. Jacquemin MG, Desqueper BG, Benhida A, Vander Elst L, Hoylaerts MF, et al. (1998) Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 92: 496-506.
12. Fulcher CA, de Graaf Mahoney S, Zimmerman TS, (1987) FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 69: 1475-1480.
13. van Helden PM, van den Berg HM, Gouw SC, Kaijen PH, Zuurveld MG, et al. (2008) IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A. Br J Haematol. 142: 644-652.
14. Aalberse RC, van der Gaag R, van Leeuwen J, (1983) Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130: 722-726.
15. Scandella D, Mattingly M, de Graaf S, Fulcher CA, (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 74: 1618-1626.
16. Fulcher CA, Lechner K, de Graaf Mahoney S, (1988) Immunoblot analysis shows changes in factor VIII inhibitor chain specificity in factor VIII inhibitor patients over time. Blood 72: 1348-1356.
17. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, et al. (1997) The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups. Blood 89: 3663-3671.
18. Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, et al. (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 86: 1811-1819.
19. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P, (2000) Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 95(2): 564-8.
20. Paschal RD, Meeks SL, Neff AT. Development of factor VIII inhibitors in two patients with moderate haemophilia A. Haemophilia. 2013 in press.
21. Reding MT, Lei S, Lei H, Green D, Gill J, et al. (2002) Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 88: 568-575.
22. Sánchez-Cuenca JM, Carmona E, Villanueva MJ, Aznar JA, (1990) Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 57: 897-908.
23. Lollar P, Hill-Eubanks DC, Parker CG, (1988) Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 263: 10451-10455.
24. Ling M, Duncan EM, Rodgers SE, Street M, Lloyd JV, (2001) Classification of the kinetics of factor VIII inhibitors in haemophilia A: plasma dilution studies are more discriminatory than time-course studies. Br J Haematol 114: 861-867.
25. Parkkinen J, Rahola A, von Bonsdorff L, Tölö H, Törmä E, (2006) A modified caprylic acid method for manufacturing immunoglobulin G from human plasma with high yield and efficient virus clearance. Vox Sang 90: 97-104.
26. Bergmann-Leitner ES, Mease RM, Duncan EH, Khan F, Waitumbi J, et al. (2008) Evaluation of immunoglobulin purification methods and their impact on quality and yield of antigen-specific antibodies. Malar J 7: 129.
27. Ejima D, Yumioka R, Tsumoto K, Arakawa T, (2005) Effective elution of antibodies by arginine and arginine derivatives in affinity column chromatography. Anal Biochem. 345: 250-257.
28. Gibbs E, Oger J, (2008) A biosensor-based characterization of the affinity maturation of the immune response against interferon-beta and correlations with neutralizing antibodies in treated multiple sclerosis patients. J Interferon Cytokine Res 28: 713-723.
29. Narita M, Yamada S, Matsuzono Y, Itakura O, Togashi T, et al. (1997) Measles virus-specific immunoglobulin G subclass response in serum and cerebrospinal fluid. Clin Diagn Virol 8: 233-239.
30. Hamilton RG, Morrison SL, (1993) Epitope mapping of human immunoglobulin-specific murine monoclonal antibodies with domain-switched, deleted and point-mutated chimeric antibodies. J Immunol Methods 158: 107-122.
31. Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgard U, et al. (2007) Recombinant versus plasma-derived FVIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 109: 4693-4697.
32. Gilles JG, Arnout J, Vermylen J, Saint-Remy JM, (1993) Anti-factor VIII antibodies of hemophiliac patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 82: 2452-2461.
33. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P, (2008) Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood 112: 1151-1153.
34. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P, (2007) Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 110: 4234-4242.
35. Lollar P, (1997) Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemostas 78: 647-651.
36. Barrow RT, Healey JF, Gailani D, Scandella D, Lollar P, (2000) Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules. Blood 95: 564-568.
37. Kessel C, Königs C, Linde R, Excuriola-Ettinghausen C, Stoll H, et al. (2008) Humoral immune responsiveness to a defined epitope on factor VIII before and after B cell ablation with rituximab. Mol Immunol 46: 8-15.
38. Raut S, Villard S, Grailly S, Gilles JG, Granier C, et al. (2003) Anti-heavy-chain monoclonal antibodies directed to the acidic regions of the factor VIII molecule inhibit the binding of factor VIII to phospholipids and von Willebrand factor. Thromb Haemost 90: 385-397.
39. Kopecky EM, Greinstetter S, Pabinger I, Buchacher A, Römisch J, et al. (2006) Mapping of FVIII inhibitor epitopes using cellulose-bound synthetic peptide arrays. J Immunol Methods. 308: 90-100.
40. Albert T, Egler C, Jakuschev S, Schuldenzucker U, Schmitt A, et al. (2008) The B-cell epitope of the monoclonal anti-factor VIII antibody ESH8 characterized by peptide array analysis. Thromb Haemost 99: 634-637.
41. Lavigne-Lissalde G, Tarrade C, Lapalud P, Chtourou S, Schved JF, et al. (2008) Simultaneous detection and epitope mapping of anti-factor VIII antibodies. Thromb Haemost 99: 1090-1096.
42. van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, et al. (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317: 1554-1557.
43. Lewis KB, Meengs B, Bondensgaard K, Chin L, Hughes SD, et al. (2009) Comparison of the ability of wild type and stabilized human IgG4 to undergo Fab arm exchange with endogenous IgG4 in vitro and in vivo. Mol Immunol 46: 3488-3494.
44. Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, et al. (2009) Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 27: 767-771.